Status and phase
Conditions
Treatments
About
To observe the efficacy of apatinib combined with AI regimen chemotherapy compared with AI regimen chemotherapy and single-agent apatinib in patients with unresectable soft tissue sarcoma. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rates (ORR, CR+PR), disease control rate (DCR, CR+PR+SD), and overall survival ( OS).
To observe the safety of apatinib combined with AI chemotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 3 patient groups
Loading...
Central trial contact
Jilong Yang, M.D., Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal